OmniActive Health Technologies, a leading global supplier of clinically studied health and wellness ingredients, has filed a patent infringement lawsuit against Indian nutraceutical firm Bio‑Gen Extracts Pvt. Ltd. in the U.S. District Court for the Eastern District of Texas.
The lawsuit centers on U.S. Patent No. 10,532,035, owned by OmniActive, which protects a proprietary formulation method for combining marigold-derived lutein and zeaxanthin isomers—key carotenoids known to support eye health. This patented technology is at the core of OmniActive’s flagship product, Lutemax® 2020, a premium eye health ingredient used in supplements worldwide.
Allegations Against Bio‑Gen Extracts
According to court filings, OmniActive alleges that Bio‑Gen’s product Lute‑gen® unlawfully uses its patented formulation method. The company claims Bio‑Gen has knowingly infringed upon several claims of its patent, specifically relating to the unique composition and ratio of lutein and zeaxanthin isomers.
OmniActive is seeking:
A jury trial
Compensatory and enhanced damages
Legal cost reimbursement
A permanent injunction against further infringement by Bio‑Gen
The plaintiff emphasized its commitment to safeguarding innovation and customer trust. “We invest heavily in research, clinical validation, and patent protection to provide high-quality, science-backed ingredients.
About the Patented Ingredient – Lutemax® 2020
Lutemax® 2020 is a marigold-derived extract that contains all three macular carotenoids—lutein, RR-zeaxanthin, and RS (meso)-zeaxanthin—in the same ratio as found in nature. Supported by multiple clinical studies, the ingredient has been widely recognized for promoting visual function, reducing eye fatigue, and combating the effects of blue light exposure.
What This Means for the Nutraceutical Industry
This case shines a spotlight on the growing competition and innovation within the nutraceutical and dietary supplement sector. Patent protection is becoming increasingly critical as companies invest in proprietary formulations to differentiate themselves in a crowded market.
About the Companies Involved
OmniActive Health Technologies Ltd.
Headquartered in Mumbai, India, with a major U.S. presence in Bridgewater, New Jersey, OmniActive is known for developing science-driven, clinically validated ingredients. Its portfolio includes actives for eye health, brain function, metabolism, and skin wellness.
Bio‑Gen Extracts Pvt. Ltd.
Based in India, Bio‑Gen is a botanical extract and nutraceutical ingredient manufacturer. Its product Lute‑gen® is marketed as a natural source of lutein and zeaxanthin for eye health supplements.